Synthesis method of B (4)-aryl-B (9)-amide-o-carborane derivative
By introducing amides into o-carboboane and palladium-catalyzed oxidative coupling using aryl trifluoroborate, the problem of selective functionalization of o-carboborane B-H bond is solved, and B(4)-aryl is achieved -B(9)-amide-o-carboborane diversified synthesis provides a technical basis for drug design.
Patent Information
- Application Number
- CN202311765818.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-29
- Filing Date
- 2023-12-21
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-12-21
AI Technical Summary
Due to the poor reactivity of the o-carboborane B-H bond, it is difficult to selective functionalize, which affects the selective control of the B(4)-H bond and the B(4)-aryl-B(9)-amide- Diversified synthesis of o-carboborane derivatives.
By introducing amide at position B(9), the B(4)-H bond activation is induced by the electron withdrawal effect of the amide, and using aryl trifluoroborate as the coupling unit, B(4) catalyzed oxidative coupling is achieved by palladium catalyzed oxidative coupling Selective arylation of )-H to obtain B(4)-aryl-B(9)-amide-o-carboborane derivative.
The selective functionalization method of o-carboborane is provided, which improves the selective control of B(4)-H bond, and realizes B(4)-aryl-B(9)-amide-o-carboborane. The diverse synthesis of the disease provides a material basis for the design of anti-tumor drugs.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic synthesis chemical synthesis, and relates to a method for synthesizing a B(4)-aryl-B(9)-amide-o-carborane derivative. Background Art
[0002] In the field of medicine, it can be used in boron neutron capture therapy, which is one of the methods for achieving effective precision treatment in cancer treatment. In addition, in drug discovery, structural diversity is a key factor in therapeutic innovation. Independent or "first-in-class" molecular entities that have not been used in drug design before can discover new therapies with significant clinical benefits. Despite the high level of investment in drug research and development, only relatively few new molecular entities are approved for clinical use each year, and carborane can provide structural diversity of compounds with different skeletons from conventional compounds, which promotes the development of new and effective biologically active compounds. In recent years, studies have shown that replacing phenyl groups with carborane can improve drug efficacy by promoting special hydrophobic interactions with protein binding sites and promoting passage through the blood-brain barrier. Carborane is more hydrophobic than adamantyl and phenyl groups, and their combination with drug analogs can favorably regulate some physical and chemical properties of the compound. Moreover, the amide group contained in the molecule can serve as an activation group for the drug target, and at the same time can improve the bioavailability and stability of the drug, etc. 1 It has been reported that amide-containing carborane derivatives can interact with receptors or enzymes such as epoxide hydrolase receptors, translocase receptors, nicotinamide phosphoribosyltransferase, and cyclooxygenase, and exhibit significant biological activities. 2 In the future, carborane will have more applications in drug discovery, chemical biology and biomolecular imaging.
[0003] Since o-carborane contains ten BH bonds with similar chemical environments and little difference in reactivity, its selective functionalization is very difficult. The present invention introduces amide at the B(9) position, using amide as a positioning group to control the selectivity of the BH bond on the one hand, and using the electron-withdrawing effect of amide to induce the activation of the B(4)-H bond on the other hand. On this basis, aryl potassium trifluoroborate is used as a coupling unit, and palladium-catalyzed oxidative coupling is used to achieve the selective arylation of B(4)-H, providing a material and technical basis for exploring the application of B(4)-aryl-B(9)-amide-o-carborane derivatives in the preparation of anti-tumor drugs.
[0004] This method provides an economical and efficient method for the selective functionalization of the BH bond of o-carborane, lays a theoretical and technical foundation for the further design of the selective functionalization of B(9)-amide-o-carborane B(4)-H, and provides a material basis for exploring the application of B(4)-aryl-B(9)-amide-o-carborane in related disciplines.
[0005] 1. Kumari, S.; Carmona, AV; Tiwari, AK; Trippier, PC. Amide BondBioisosteres: Strategies, Synthesis, and Successes. J. Med. Chem. 2020, 63, 12290-12358.
[0006] 2. Marfavi, A.; Kavianpour, P.; Rendina, LM, Carboranes in drug discovery, chemical biology and molecular imaging. Nat Rev Chem. 2022, 6, 486-504. Summary of the invention
[0007] The purpose of the present invention is to utilize the electron-withdrawing effect of amide to induce the activation of B(4)-H, use aryl potassium trifluoroborate as the aryl source, and realize the selective arylation of B(9)-amide-o-carborane B(4)-H under mild conditions, thereby obtaining a series of B(4)-aryl-B(9)-amide-o-carborane derivatives.
[0008] In a first aspect, the present invention provides a B(4)-aryl-B(9)-amide-o-carborane derivative, wherein the derivative is represented by the following general formula (1).
[0009]
[0010] Wherein, R1 is one of phenyl, substituted phenyl, benzyl, benzylnaphthalene or cyclopropyl;
[0011] The R2 is one of phenyl, substituted phenyl or naphthyl.
[0012] Preferably, the substituent of the substituted phenyl group is one of halogen, methyl, methoxy, trifluoromethyl, tert-butyl and acetyl.
[0013] Preferably, the substituent of the substituted phenyl group in R1 is one of halogen, methyl, methoxy, trifluoromethyl, and tert-butyl; the substituent of the substituted phenyl group in R2 is one of halogen, methyl, methoxy, trifluoromethyl, tert-butyl, and acetyl.
[0014] In a second aspect, the present invention provides a method for preparing a B(4)-aryl-B(9)-amide-o-carborane derivative, wherein the method for preparing the derivative is represented by the following general formula (2):
[0015]
[0016] Using B(9)-amide-o-carborane as raw material, 10 mol% Pd(MeCN)4(BF4)2 as catalyst, 2 eq Cu(OAc)2 and 1 eq Ag2O as oxidants, the reaction was carried out in tetrahydrofuran at 50°C for 24 h under argon atmosphere. The selective oxidative coupling of aryl potassium trifluoroborate and B(4)-H was used to efficiently achieve the diversified synthesis of B(4)-aryl-B(9)-amide-o-carborane derivatives.
[0017] Wherein, R1 is one of phenyl, substituted phenyl, benzyl, benzylnaphthalene or cyclopropyl;
[0018] The R2 is one of phenyl, substituted phenyl or naphthyl.
[0019] Preferably, the substituent of the substituted phenyl group is one of halogen, methyl, methoxy, trifluoromethyl, tert-butyl and acetyl.
[0020] Preferably, the substituent of the substituted phenyl group in R1 is one of halogen, methyl, methoxy, trifluoromethyl, and tert-butyl; the substituent of the substituted phenyl group in R2 is one of halogen, methyl, methoxy, trifluoromethyl, tert-butyl, and acetyl.
[0021] Preferably, the reaction temperature is 50°C.
[0022] Preferably, the reaction atmosphere is argon.
[0023] Preferably, the method for preparing the B(4)-aryl-B(9)-amide-o-carborane derivative further comprises a method for preparing a raw material 9-amide-o-carborane derivative, the method comprising:
[0024] (1) reacting an o-carborane derivative with dichloromethane, I2 and AlCl3 catalyst to obtain a 9-Io-carborane derivative;
[0025] (2) 9-Io-carborane derivatives react with benzamide, Pd2(dba)3, K3PO4, DavePhos and toluene to obtain 9-amide-o-carborane derivatives;
[0026] Preferably, the method further comprises:
[0027] (3) Filtration, concentration, and separation: After the reaction in step (2) is completed, the system temperature is cooled to room temperature and filtered through a short silica gel column using ethyl acetate as the eluent. The filtrate is concentrated under reduced pressure and then purified by column chromatography using petroleum ether / ethyl acetate = 5:1 as the eluent to obtain a B(4)-aryl-B(9)-amide-o-carborane derivative.
[0028] Preferably, taking 9-Io-carborane as an example, the formula is:
[0029] The first step: the o-carborane derivative is reacted with dichloromethane, I2 and AlCl3 catalyst to obtain a 9-Io-carborane derivative;
[0030]
[0031] Under argon atmosphere, o-carborane derivative (1.44 g, 10 mmol), dry dichloromethane (DCM) (30 mL), I2 (2.54 g, 10 mmol) and catalytic amount of AlCL3 were added to a dry 100 mL round-bottom flask in sequence. The speed of the magnetic stirrer was adjusted and the reaction flask was placed in a 40 ° C oil bath. The degree of reaction was detected by TLC plate. After the reaction was completed, water was added to the system to quench. The reaction system was extracted with ethyl acetate, washed with saturated NaHCO3 and NaCl aqueous solutions for several times, and then the extract was dried with anhydrous Na2SO4. After reduced pressure concentration, the crude product was recrystallized to obtain 2.45 g of the target product with a yield of 90%.
[0032] Step 2: 9-Io-carborane reacts with benzamide, Pd2(dba)3, K3PO4, DavePhos and toluene to obtain 9-amide-o-carborane derivatives;
[0033]
[0034] Under argon protection, 9-Io-carborane (1g, 3.7mmol), benzamide (1343mg, 11.1mmol), Pd2(dba)3 (84mg, 2.5mol%), K3PO4 (3.92g, 18.5mmol), davephos (72mg, 0.05mmol), and 15mL of toluene were added to a dry 100mL round-bottom flask in sequence. After adjusting the speed of the stirrer, the reaction bottle was placed in a 100℃ oil bath for reaction. The reaction was detected by TLC. After the reaction was completed and the system temperature was cooled to room temperature, it was filtered on a short silica gel column with ethyl acetate as the eluent. After the filtrate was concentrated under reduced pressure, it was separated and purified by column chromatography with petroleum ether / ethyl acetate = 5:1 as the eluent. 537.2mg of the product was obtained by column chromatography with a yield of 55%.
[0035] In a third aspect, the present invention provides the use of the B(4)-aryl-B(9)-amide-o-carborane derivative described in the first aspect in the preparation of anti-tumor drugs.
[0036] Beneficial effects:
[0037] 1) The method for arylating B(9)-amide-o-carborane B(4)-H designed by the present invention is simple to operate. The reaction uses stable potassium phenyltrifluoroborate as the aromatic source and achieves the selective arylation of B(4)-H with excellent regioselectivity under anhydrous conditions.
[0038] 2) The present invention provides a novel method for the selective functionalization of o-carborane, and provides a new idea for further designing the selective functionalization of o-carborane B(4)-H and the diversified synthesis of o-carborane derivatives. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 is the general formula of B(4)-aryl-B(9)-amide-o-carborane derivative;
[0040] Figure 2 is the general formula for the preparation of B(4)-aryl-B(9)-amide-o-carborane derivatives;
[0041] Figure 3 A method for preparing a 9-Io-carborane derivative;
[0042] Figure 4 A method for preparing a 9-amide-o-carborane derivative;
[0043] Figure 5 The reaction formula for preparing B(4)-aryl-B(9)-amide-o-carborane;
[0044] Figure 6 Reaction conditions for preparing B(4)-aryl-B(9)-amide-o-carborane;
[0045] Figure 7 It is a substrate expansion for B(4)-aryl-B(9)-amide-o-carborane derivatives;
[0046] Figure 8 is the preparation reaction formula of compound 2a;
[0047] Fig. 9 is the preparation reaction formula of compound 2b;
[0048] Fig.10 is the preparation reaction formula of compound 2c;
[0049] Fig.11 is the preparation reaction formula of compound 2d;
[0050] Fig.12 is the preparation reaction formula of compound 2e;
[0051] Fig.13 is the preparation reaction formula of compound 2f;
[0052] Fig.14 is the preparation reaction formula of compound 2g;
[0053] Fig.15 is the preparation reaction formula of compound 2h;
[0054] Fig.16 is the preparation reaction formula of compound 2i;
[0055] Fig.17 is the preparation reaction formula of compound 2j;
[0056] Fig.18 is the preparation reaction formula of compound 2k;
[0057] Fig.19 is the preparation reaction formula of compound 21;
[0058] Fig. 20 is the preparation reaction formula of compound 2m;
[0059] Fig.21 is the preparation reaction formula of compound 2n;
[0060] Fig. 22 is the preparation reaction formula of compound 2o;
[0061] Fig.23 is the preparation reaction formula of compound 2p;
[0062] Fig.24 is the preparation reaction formula of compound 2q;
[0063] Fig.25 is the preparation reaction formula of compound 2r;
[0064] Fig.26 is the preparation reaction formula of compound 2s;
[0065] Fig. 27 is the preparation reaction formula of compound 2t;
[0066] Fig.28 is the preparation reaction formula of compound 2u;
[0067] Fig.29 is the preparation reaction formula of compound 2v;
[0068] Fig.30 is the preparation reaction formula of compound 2w;
[0069] Fig.31 is the preparation reaction formula of compound 2y;
[0070] Fig.32 This is the reaction formula for preparing compound 2z. DETAILED DESCRIPTION
[0071] Example 1 Evaluation of different preparation processes:
[0072] Taking B(9)-amide-o-carborane (1a) and potassium phenyltrifluoroborate as raw materials to prepare B(4)-aryl-B(9)-amide-o-carborane (2a) as an example, the reaction conditions were evaluated as follows. The reaction conditions are shown in Table 1 below:
[0073]
[0074] Table 1 Reaction conditions
[0075] Entry Catalyst Oxidant Solvent <![CDATA[Yield b ]]> 1 <![CDATA[Pd(OAc)2]]> <![CDATA[Cu(OAc)2]]> THF 42.8 2 <![CDATA[Pd(OAc)2]]> <![CDATA[Cu(OAc)2]]> toluene 23.3 3 <![CDATA[Pd(OAc)2]]> <![CDATA[Cu(OAc)2]]> <![CDATA[CH3CN]]> 32.2 4 <![CDATA[Pd(OAc)2]]> <![CDATA[Cu(OAc)2]]> HFIP 26.7 5 <![CDATA[Pd(MeCN)2Cl2]]> <![CDATA[Cu(OAc)2]]> THF 33.3 6 <![CDATA[Pd(TFA)2]]> <![CDATA[Cu(OAc)2]]> THF 36.6 7 <![CDATA[Pd(MeCN)4(BF4)2]]> <![CDATA[Cu(OAc)2]]> THF 50 8 <![CDATA[Pd(MeCN)4(BF4)2]]> <![CDATA[Ag2O]]> THF 53.2 9 <![CDATA[Pd(MeCN)4(BF4)2]]> <![CDATA[Ag2CO3]]> THF 40.4 10 <![CDATA[Pd(MeCN)4(BF4)2]]> <![CDATA[AgNO3]]> THF 46 11 <![CDATA[Pd(MeCN)4(BF4)2]]> AaC THF 51.5 12 <![CDATA[Pd(MeCN)4(BF4)2]]> <![CDATA[AgBF4]]> THF 45.6 13 <![CDATA[Pd(MeCN)4(BF4)2]]> <![CDATA[AgOAc+Cu(OAc)2 d ]]> THF 68.9 14 <![CDATA[Pd(MeCN)4(BF4)2]]> <![CDATA[Ag2O+Cu(OAc)2 d ]]> THF <![CDATA[75(69 c )]]>
[0076] Note: All reactions were performed using 0.1 mmol 1a, 0.3 mmol potassium phenyltrifluoroborate, 10 mol% catalyst, 0.2 mmol oxidant, and 1 mL solvent under argon atmosphere for 24 h. b GC yield, c Isolated yield, d 0.2mmol silver salt and 0.1mmol copper salt.
[0077] The results show that B(4)-aryl-B(9)-amide-o-carborane derivatives can be prepared under the above-mentioned different preparation process conditions. Among them, taking B(4)-aryl-B(9)-amide-o-carborane (2a) as an example, the optimal synthesis conditions are the reaction conditions corresponding to number 14 in Table 1: B(9)-amide-o-carborane 1a (0.1mmol, 26.3mg), potassium phenyltrifluoroborate (0.3mmol, 55.2mg), Pd(MeCN)4(BF4)2 (10mol%, 4.5mg) as catalyst, Ag2O (2eq, 46mg) and Cu(OAc)2 (1eq, 20mg) as oxidants, reacted in 1mLTHF at 50℃ for 24h.
[0078] Example 2 Substrate expansion:
[0079] According to the reaction conditions of the above-mentioned different preparation processes, after replacing other reaction substrates, the reaction formula, i.e. the corresponding synthetic product, is as follows:
[0080]
[0081] The specific synthesis method and results are as follows:
[0082] 1. Preparation of compound 2a:
[0083]
[0084] Under argon atmosphere, B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol), dry THF (1 mL), potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol), palladium tetraacetonitrile tetrafluoroborate (4.5 mg, 10 mol%), silver oxide (46 mg, 0.2 mmol), copper acetate (20 mg, 0.1 mmol) were added to a dry 10 mL round-bottom flask in sequence, and the round-bottom flask was placed in a 50° C. oil bath for 24 h (the reaction equation is shown above), and the reaction was monitored by TLC. After the reaction was completed, the system was first filtered with filter paper, concentrated under reduced pressure, and then separated and purified by column chromatography, using petroleum ether / ethyl acetate = 4:1 to 3:1 as the eluent, and column chromatography was used to obtain 23.4 mg of product 2a, with a yield of 69%, which was in line with expectations.
[0085] NMR data: 1HNMR (500MHz, CDCl3, ppm): δ7.63-7.61 (m, 4H), 7.43-7.39 (m, 1H), 7.35-7.28 (m, 5H), 5.69 (s, 1H), 3.71 (s, 2H); 13C{1H}NMR (125MHz, CDCl3, ppm): δ169.3, 135.8, 134 .1,131.0,128.9,128.3,128.0,127.0,52.3,47.5; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.5(1B),-2.3(2B),-3.7(2B),-9.8(2B),-14.2(1B),-16.8(2B); HRMS(ESI)m / zcalcd for C 15 H 22 B 10 NO + (M+H) + 340.26991, found 340.27090.
[0086] 2. Preparation of compound 2b:
[0087]
[0088] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 3-fluorophenyl trifluoroborate (60.6 mg, 0.3 mmol). The other methods were the same as those described in the above 1.
[0089] (The reaction equation is shown above). Column chromatography was used to separate 19.7 mg of product 2b. The yield was 58%, which was in line with expectations.
[0090] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.75-7.74 (d, 2H, J = 12Hz), 7.63-7.62 (m, 2H), 7.54-7.53 (d, 2H, J = 12Hz), 7.44-7.41 (m, 1H), 7.37-7.34 (m, 2H), 5.70 (s, 1H), 3.74 (s, 2H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ169.2, 163.3-161.7 (J = 245 Hz),135.7,131.1,129.8-129.7(J=6Hz),129.7,128.4,127.0,120.6-120.5(J=21Hz),115.9-115.8(J=20Hz),52.3,47 .5; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.6(1B),-2.3(1B),-4.4(2B),-9.9(2B),-14.4(1B),-17.1(3B); HRMS(ESI)m / z calcd for C 15 H 19 B 10 FNO - (MH) - 357.24230, found 357.24359.
[0091] 3. Preparation of compound 2c
[0092]
[0093] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 4-fluorophenyl trifluoroborate (60.6 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 15.9 mg of the product 2c. The yield was 47%, which was in line with expectations.
[0094] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.63-7.59 (m, 4H), 7.43-7.41 (dd, 1H, J = 12Hz), 7.36-7.33 (dd, 2H, J = 12Hz), 7.00-6.97 (dd, 2H, J = 12Hz), 5.68 (S, 1H), 3.72 (S, 1H), 3.68 (S, 1H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ169. 3,164.5-162.8(J=248Hz),136.1-136.1(J=9Hz),131.2,128.4,127.0,115.1-115.0(21Hz),52.5,47.5; 11B{ 1H}NMR (160MHz, CDCl3, ppm): δ6.6 (1B), -2.3 (2B), -3.9 (2B), -9.8 (2B), -14.7 (1B), -17.0 (2B); HRMS (ESI) m / z calcd for C 15 H 19 B 10 FNO - (MH) - 357.24230, found 357.24356.
[0095] 4. Preparation of compound 2d
[0096]
[0097] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 4-chlorophenyl trifluoroborate (65.5 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 15.7 mg of the product 2d. The yield was 42%, which was in line with expectations.
[0098] NMR data: 1H NMR (600 MHz, CDCl3, ppm): δ7.63-7.62 (d, 2H, J = 6 Hz), 7.56-7.54 (d, 2H, J = 6 Hz), 7.44-7.41 (m, 1H), 7.36-7.34 (m, 2H), 7.27-7.26 (m, 2H), 5.68 (s, 1H), 3.72 (s, 1H), 3.69 (s, 1H); 13C{1H} NMR (150M Hz, CDCl3, ppm): δ169.3,135.6,135.5,135.4,131.2,128.4,128.2,127.0,52.4,47.5; 11B{1H}NMR(1 60MHz, CDCl3, ppm): δ6.5(1B),-2.3(2B),-4.1(2B),-9.8(2B),-14.4(1B),-17.1(2B); HRMS(ESI)m / z calcd for C 15 H 19 B 10 ClNO - (MH) - 373.21275, found 373.21262.
[0099] 5. Preparation of compound 2e
[0100]
[0101] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 3-bromophenyl trifluoroborate (78.9 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 15.7 mg of the product 2e. The yield was 38%, which was in line with expectations.
[0102] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.73 (s, 1H), 7.65-7.61 (m, 2H), 7.55-7.54 (d, 1H, J = 6Hz), 7.46-7.41 (m, 2H), 7.37-7.33 (m, 2H), 7.17-7.15 (dd, 1H, J = 6Hz), 5.69 (s, 1H), 3.72 (s, 2H); 13C{1H}NMR (150MHz , CDCl3, ppm): δ169.4,136.6,132.7,132.0,131.2,129.8,128.4,127.0,122.6,52.2,47.5; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.5(1B),-2.3(2B),-4.6(2B),-9.8(2B),-14.3(1B),-16.9(2B); HRMS(ESI)m / z calcd forC 15 H 19 B 10 BrNO - (MH) - 416.16587, found 416.16794.
[0103] 6. Preparation of Compound 2f
[0104]
[0105] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 4-bromophenyl trifluoroborate (78.9 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2f (16.6 mg) was separated by column chromatography. The yield was 40%, which was in line with expectations.
[0106] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.64-7.62 (m, 2H), 7.50-7.48 (m, 2H), 7.44-7.41 (m, 3H), 7.37-7.33 (m, 2H), 5.68 (s, 1H), 3.71 (s, 1H), 3.68 (s, 1H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ169.2,135.8,135.6,131.2,131.2,128.4,127.0,123.9,52.3,47.5; 11B{1H}NMR (160MHz, C DCl3, ppm): δ6.6(1B),-2.2(2B),-4.0(2B),-9.8(2B),-14.4(1B),-17.0(2B); HRMS(ESI)m / z calcd for C 15 B 10 H 19 NOB - (MH) - 418.16382, found 418.16357.
[0107] 7. Preparation of Compound 2g
[0108]
[0109] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 4-CF3 phenyl trifluoroborate (75.6 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 2 g 24 mg of the product. The yield was 59%, which was in line with expectations.
[0110] NMR data: 1HNMR (500MHz, CDCl3, ppm): δ7.75-7.74 (d, 2H, J = 10Hz), 7.63-7.62 (m, 2H), 7.54-7.53 (d, 2H, J = 10Hz), 7.44-7.41 (m, 1H), 7.37-7.34 (dd, 2H, J = 8Hz), 5.70 (s, 1H), 3.74 (s, 2H); 13C{1H}NMR (125MHz , CDCl3, ppm): δ169.2,134.4,131.2,128.4,127.0,124.7-124.6 (J=3.8Hz),52.3,47.5; 11B{1H}NMR ( 160MHz, CDCl3, ppm): δ6.6(1B),-2.2(2B),-4.5(2B),-9.8(2B),-14.4(1B),-17.0(2B); HRMS(ESI)m / z calcd forC 16 H 19 B 10 F3NO - (MH) - 407.23911, found 407.24017.
[0111] 8. Preparation of Compound 2h
[0112]
[0113] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 4-acetylphenyl trifluoroborate (67.8 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2h was separated by column chromatography (13 mg). The yield was 33.1%, which was in line with expectations.
[0114] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.87-7.85 (m, 2H), 7.73-7.72 (m, 2H), 7.63-7.62 (m, 2H), 7.44-7.41 (m, 1H), 7.36-7.33 (m, 2H), 5.71 (s, 1H), 3.74 (s, 2H), 2.56 (s, 3H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ198.2,169.3,137.2,134.3,131.2,128.4,127.6,127.5,127.0,127.0,52.2,47.5,26.6; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.6(1B),-2.3(2B),-4.5(2B),-9.7(2B),-14.2(1B),-16.9(2B); HRMS(ESI)m / z calcd for C 17 H 24 B 10 NO2 + (M+H) + 382.28047, found 382.28088.
[0115] 9. Preparation of Compound 2i
[0116]
[0117] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 2-methylphenyl trifluoroborate (59.4 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 25 mg of the product 2i. The yield was 71%, which was in line with expectations.
[0118] NMR data: 1HNMR (500MHz, CDCl3, ppm): δ7.64-7.63 (d, 1H, J = 10Hz), 7.61-7.59 (m, 2H), 7.42-7.39 (m, 1H), 7.34-7.31 (m, 2H), 7.22-7.19 (m, 1H), 7.14-7.12 (dd, 2H, J = 10Hz), 5.69 (s, 1H), 3.90 (s, 1H), 3.67 (s, 1H), 2.58 (s, 3H); 13C{1H}N MR (125MHz, CDCl3, ppm): δ169.1,142.2,136.7,135.9,131.1,131.0,128.8,128.3,127.0,125.5,51.8,47.2,23.8; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.6(1B),-3.1(1B),-4.1(1B),-9.6(2B),-14.0(1B),-17.2(4B); HRMS(ESI)m / z calcd for C 16 H 22 B 10 NO - (MH) - 353.26737, found 353.26849.
[0119] 10. Preparation of Compound 2j
[0120]
[0121] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 3-methylphenyl trifluoroborate (59.4 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 26.5 mg of product 2j. The yield was 75%, which was in line with expectations.
[0122] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.64-7.62 (m, 2H), 7.41-7.39 (m, 3H), 7.35-7.32 (m, 2H), 7.22-7.18 (dd, 1H, J = 12Hz), 7.15-7.13 (d, 1H, J = 12Hz), 5.69 (s, 1H), 3.70 (s, 1H), 2.31 (s, 3H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ7.64-7.62 (m, 2H), 7.41-7.39 (m, 3H), 7.35-7.32 (m, 2H), 7.22-7.18 (dd, 1H, J = 12Hz), 7.15-7.13 (d, 1H, J = 12Hz), 5.69 (s, 1H), 3.70 (s, 1H), 2.31 (s, 3H); l3, ppm): δ169.2,137.4,135.9,134.8,131.2,131.0,129.7,128.3,128.0,127.0,52.2,47.4,21.4; 11B{1 H}NMR (160MHz, CDCl3, ppm): δ6.5 (1B), -2.4 (2B), -3.7 (1B), -9.8 (2B), 14.2 (1B), 17.0 (3B); HRMS (ESI) m / z calcdfor C 16 B 10 H 22 NO - (MH) - 352.27101, found 352.27127.
[0123] 11. Preparation of compound 2k
[0124]
[0125] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 4-methylphenyl trifluoroborate (59.4 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 23 mg of the product 2k. The yield was 65%, which was in line with expectations.
[0126] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.64-7.62 (m, 2H), 7.52-7.50 (d, 2H, J = 12Hz), 7.43-7.39 (m, 1H), 7.36-7.32 (m, 2H), 7.13-7.11 (d, 2H, J = 12Hz), 5.69 (s, 1H), 3.70 (s, 1H), 3.67 (s, 1H), 2.31 (s, 3H); 13C{1H}NMR( 150MHz, CDCl3, ppm): δ169.2,138.9,135.8,134.2,131.0,128.9,128.3,127.1,52.3,47.5,21.3; 11B{1H} NMR (160MHz, CDCl3, ppm): δ6.5 (1B), -2.4 (1B), -3.7 (2B), -9.9 (2B), -14.4 (1B), -17.1 (3B); HRMS (ESI) m / z calcd forC 16 B 10 H 22 NO - (MH) - 352.27101, found 352.27145.
[0127] 12. Preparation of Compound 21
[0128]
[0129] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 4-tert-butylphenyl trifluoroborate (72 mg, 0.3 mmol). The other methods were the same as described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 24 mg of the product 21. The yield was 61%, which was in line with expectations.
[0130] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.65-7.62 (m, 2H), 7.57-7.55 (d, 2H, J = 12Hz), 7.43-7.40 (m, 1H), 7.36-7.32 (dd, 4H, J = 12Hz), 5.70 (s, 1H), 3.69 (s, 2H), 1.29 (s, 9H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ169.2,151.9,135.9,134.2,134.0,131.0,128.3,127.1,125.0,52.3,47.4,34.6,31.2; 11B{1H}NMR ( 160MHz, CDCl3, ppm): δ6.5(1B),-2.3(1B),-3.6(2B),-9.9(2B),-14.3(1B),-17.2(3B); HRMS(ESI)m / z calcd for C 19 B 10 H 28 NO - (MH) - 394.31796, found 394.31775.
[0131] 13. Preparation of Compound 2m
[0132]
[0133] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 3-methoxyphenyl trifluoroborate (64.2 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2m was separated by column chromatography (29.2 mg). The yield was 79%, which was in line with expectations.
[0134] NMR data: 1H NMR (600 MHz, CDCl3, ppm): δ7.65-7.63 (m, 2H), 7.43-7.40 (m, 2H), 7.35-7.33 (dd, 2H, J = 6 Hz), 7.24-7.21 (dd, 1H, J = 6 Hz), 7.19-7.18 (m, 2H), 5.71 (s, 1H), 3.75 (s, 3H), 3.70 (s, 2H); 13C{1H} NMR (150 MHz, CDCl3, p pm): δ169.2,159.1,135.8,131.1,129.2,128.3,127.0,126.3,119.5,114.6,55.1,52.3,47.4; 11B{1H}NMR ( 160MHz, CDCl3, ppm): δ6.5(1B),-2.4(1B),-3.9(2B),-9.9(2B),-14.3(1B),-17.3(3B); HRMS(ESI)m / zcalcd for C 16 H 22 B 10 NO2 - (MH) - 369.26229, found 369.26340.
[0135] 14. Preparation of Compound 2n
[0136]
[0137] The potassium phenyl trifluoroborate (55.2 mg, 0.3 mmol) in the above 1 was replaced by potassium 1-naphthylphenyl trifluoroborate (71 mg, 0.3 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Column chromatography was used to obtain 29.6 mg of the product 2n. The yield was 75.6%, which was in line with expectations.
[0138] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ8.75-8.73 (d, 1H, J = 6Hz), 7.95 (m, 1H), 7.85-7.83 (dd, 2H, J = 6Hz), 7.52-7.49 (m, 3H), 7.48-7.45 (dd, 1H, J = 6Hz), 7.43-7.40 (m, 1H), 7.35-7.33 (m, 1H), 7.26-7.23 (m, 2H), 5.70 (s, 1H), 3.93 (s, 1H), 3.71 (s, 1H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ169.2,136.1,135.8,133.8,131.0,130.2,130.2,129.2,128.2,127.1,127.0,127.0,126.2,125.3,125. 2,52.5,47.3; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.8(1B),-2.7(2B),-4.0(2B),-9.5(2B),-13.6(1B),-16.9(2B); HRMS(ESI)m / z calcd forC 19 H 22 B 10 NO - (MH) - 389.26737, found 389.26923.
[0139] 15. Preparation of compound 2o
[0140]
[0141] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 4-methyl-B(9)-amide-o-carborane 1a (27.7 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2o was separated by column chromatography to obtain 19.1 mg. The yield was 54%, which was in line with expectations.
[0142] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.62-7.61 (d, 2H, J = 6Hz), 7.53-7.51 (d, 2H, J = 6Hz), 7.32-7.28 (m, 3H), 7.14-7.12 (d, 2H, J = 6Hz), 5.67 (s, 1H), 3.70 (s, 2H), 2.34 (s, 3H); 13C{1H}NMR (150MHz, CDCl3, p pm): δ169.3,141.4,134.1,132.9,129.0,128.9,128.0,127.9,127.0,52.3,47.4,21.3; 11B{1H}NMR ( 160MHz, CDCl3, ppm): δ6.5(1B),-2.4(1B),-3.8(2B),-9.8(2B),-14.4(1B),-17.2(3B); HRMS(ESI)m / z calcd for C 16 H 22 B 10 NO - (MH) - 353.26737, found 353.26849.
[0143] 16 Preparation of compound 2p
[0144]
[0145] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 3-methyl-B(9)-amide-o-carborane 1a (27.7 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). Under argon atmosphere, 3-methyl-B(9)-amide-o-carborane 1a (27.7 mg, 0.1 mmol), dry THF (1 mL), potassium phenyltrifluoroborate (55.2 mg, 0.3 mmol), tetraacetonitrile palladium tetrafluoroborate (4.5 mg, 10 mol%), silver oxide (46 mg, 0.2 mmol), and copper acetate (20 mg, 0.1 mmol) were added in sequence to a dry 10 mL round-bottom flask. The round-bottom flask was placed in an oil bath at 50° C. for reaction for 24 h, and the progress of the reaction was monitored by TLC thin layer plate. After the reaction, the system was filtered with filter paper, concentrated under reduced pressure, and then purified by column chromatography. Petroleum ether / ethyl acetate = 4:1-3:1 was used as eluent. The product 2p19.1 mg was obtained by column chromatography. The yield was 54%, which was in line with expectations.
[0146] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.63-7.62 (d, 2H, J = 6Hz), 7.45 (s, 1H), 7.40-7.39 (m, 1H), 7.33-7.30 (m, 3H), 7.22-7.21 (m, 2H), 5.68 (s, 1H), 3.70 (s, 2H), 2.32 (s, 3H), 13C{1H}NMR (150MHz, CDCl3, ppm): δ169.5,138.1,135.7,134.2,131.8,128.9,128.2,128.0,127.9,124.0,52.3,47.5,21.3; 11B{1H}NMR ( 160MHz, CDCl3, ppm): δ6.5(1B),-2.4(2B),-3.7(2B),-10.1(2B),-14.6(1B),-17.8(2B); HRMS(ESI)m / z calcd for C 16 H 22 B 10 NO - (MH) - 353.26737, found 353.26855.
[0147] 17. Preparation of Compound 2q
[0148]
[0149] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 4-methoxy-B(9)-amide-o-carborane 1a (29.3 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2q was separated by column chromatography to obtain 19.2 mg. The yield was 52%, which was in line with expectations.
[0150] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.62-7.59 (m, 4H), 7.33-7.30 (m, 3H), 6.83-6.82 (m, 2H), 5.62 (s, 1H), 3.80 (s, 3H), 3.69 (s, 2H), 13C{1H}NMR (150MHz, CDCl3, ppm): δ168.7, 161.9,134.2,128.9,128.8,128.0,113.5,55.3,52.2,47.3; 11B{1H}NMR (160MHz, CDCl3 ,ppm): δ6.6(1B),-2.3(2B),-3.8(2B),-9.8(2B),-14.2(1B),-17.0(2B); HRMS(ESI)m / z calcd for C 16 H 22 B 10 NO2 - (MH) - 369.26229, found 369.26358.
[0151] 18. Preparation of Compound 2r
[0152]
[0153] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 2-methoxy-B(9)-amide-o-carborane 1a (29.3 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product r was separated by column chromatography to obtain 14.4 mg of product r. The yield was 39%, which was in line with expectations.
[0154] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.62-7.59 (m, 4H), 7.33-7.28 (m, 3H), 6.83-6.82 (m, 2H), 5.62 (s, 1H), 3.80 (s, 3H), 3.69 (s, 2H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ166.9, 157.5, 134 .2,133.0,132.5,132.4,128.8,128.0,121.1,111.4,55.6,51.9,47.3; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.8(1B),-2.5(2B),-4.2(2B),-9.6(2B),-14.0(1B),-16.8(2B); HRMS(ESI)m / z calcd for C 16H 22 B 10 NO2 - (MH) - 369.26229, found 369.26352.
[0155] 19. Preparation of Compound 2s
[0156]
[0157] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 4-tert-butyl-B(9)-amide-o-carborane 1a (31.9 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2s was separated by column chromatography to obtain 20.1 mg. The yield was 51%, which was in line with expectations.
[0158] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.63-7.61 (d, 2H, J = 6Hz), 7.57-7.56 (d, 2H, J = 6Hz), 7.36-7.35 (m, 1H), 7.34 (s, 1H), 7.33-7.31 (m, 2H), 7.30-7.29 (m, 1H), 5.68 (s, 1H), 3.70 (s, 2H); 13C{1H}NMR (150MHz, CDCl3, ppm): δ169.1,154.5,134.1,133.5,132.9,128.9,128.1,128.0,126.9,125.4,125.2,52.3,47.4,34.8,31.1; 11B{1 H}NMR (160MHz, CDCl3, ppm): δ6.6 (1B), -2.4 (1B), -3.8 (2B), -9.8 (2B), -14.3 (1B), -17.1 (3B); HRMS (ESI) m / z calcd for C 19 H 28 B 10 NO - (MH) - 395.31432, found 395.31573.
[0159] 20. Preparation of Compound 2t
[0160]
[0161] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by B(9)-cyclopropylamide-o-carborane 1a (22.7 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2t was separated by column chromatography to obtain 20.6 mg. The yield was 68%, which was in line with expectations.
[0162] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.60-7.58 (m, 2H), 7.36-7.32 (m, 3H), 5.19 (s, 1H), 3.66 (s, 1H), 3.63 (s, 1H), 1.19-1.17 (m, 1H), 0.91-0.88 (m, 1H), 0.84-0.83 (m, 1H), 0.64-0.59 (m, 2H); 13C{1H} NMR (150MHz, CDCl3, ppm): δ175.6,134.3,128.9,128.0,52.2,47.1,16.0,7.5,7.3; 11B{1H}NMR(16 0MHz, CDCl3, ppm): δ6.3(1B),-2.5(1B),-3.9(2B),-9.9(2B),-14.4(2B),-17.2(2B); HRMS(ESI)m / z calcd for C 12 H 20 B 10 NO - (MH) - 302.25536, found 302.25620.
[0163] 21. Preparation of Compound 2u
[0164]
[0165] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by B(9)-benzylamide-o-carborane 1a (22.7 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2u was separated by column chromatography to obtain 18.7 mg. The yield was 53%, which was in line with expectations.
[0166] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.47-7.46 (d, 2H, J = 6Hz), 7.37-7.34 (dd, 1H, J = 6Hz), 7.29-7.27 (dd, 2H, J = 6Hz), 7.20-7.19 (m, 3H), 7.00-6.99 (m, 2H), 4.93 (s, 1H), 3.65 (s, 1H), 3.62 (s, 1H), 3.42 (s, 2H); 13C{1H}N MR (150MHz, CDCl3, ppm): δ173.2,135.4,134.0,129.2,128.8,128.7,128.0,126.9,52.1,47.5,45.1; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.2(1B),-2.7(1B),-3.9(2B),-10.0(2B),-14.4(1B),-17.0(3B); HRMS(ESI)m / z calcd for C 16 H 22 B 10 NO - (MH) - 353.26737, found 353.26840.
[0167] 22. Preparation of Compound 2v
[0168]
[0169] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by B(9)-benzylnaphthalene amide-o-carborane 1a (22.7 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2v was separated by column chromatography to obtain 23.4 mg. The yield was 58%, which was in line with expectations.
[0170] NMR data: 1H NMR (500 MHz, CDCl3, ppm): δ7.82-7.80 (d, 1H, J = 10 Hz), 7.73-7.71 (d, 2H, J = 10 Hz), 7.46-7.43 (m, 1H,), 7.37-7.33 (m, 1H), 7.32-7.29 (m, 4H), 7.18-7.15 (m, 3H), 4.92 (s, 1H), 3.86 (m, 2H), 3.59 (s, 1H), 3.55 (s, 1H); 13C{1H} NMR (125M Hz, CDCl3, ppm): δ168.0,139.2,134.1,133.4,132.9,132.6,129.1,128.1,127.4,125.4,125.4,124.8,122.6,52.4,47 .9; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.3(1B),-2.4(2B),-3.7(1B),-9.9(2B),-14.4(1B),-17.1(3B); HRMS(ESI)m / z calcd for C 20 H 26 B 10 NO + (M+H) + 406.29395, found 406.29556.
[0171] 23. Preparation of Compound 2w
[0172]
[0173] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 2-fluoro B(9)-amide-o-carborane 1a (28.1 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2w was separated by column chromatography to obtain 17.9 mg of the product. The yield was 50%, which was in line with expectations.
[0174] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ8.00-7.97 (m, 1H), 7.62-7.61 (m, 2H), 7.37-7.36 (m, 1H), 7.33-7.29 (m, 3H), 7.18-7.15 (m, 1H), 7.01-6.97 (m, 1H), 6.27-6.25 (d, 1H, J = 12Hz), 3.71 (s, 2H); 13C{1H}NMR (150MHz, CDCl3, ppm): 165.0-165.0 (J = 3Hz) ,161.4,159.7,134.0,132.9-132.8(J=9Hz),132.2-132.2(J=5Hz),128.9,128.0,124.5,124.5,115.9-115.8(J=24Hz),52. 1,47.6; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.4(1B),-2.4(2B),-3.9(2B),-9.8(2B),-14.2(1B),-17.1(3B); HRMS(ESI)m / z calcd forC 15 H 19 B 10 FNO - (MH) - 357.24230, found 357.24350.
[0175] 24. Preparation of Compound 2x
[0176] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 3-fluoro B(9)-amide-o-carborane 1a (28.1 mg, 0.1 mmol). The other methods were the same as those described in the above 1. The product 2 x 16.8 mg was obtained by column chromatography. The yield was 47%, which was in line with expectations.
[0177] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.62-7.61 (m, 2H), 7.35-7.35 (m, 1H), 7.34-7.33 (m, 2H), 7.32-7.31 (m, 2H), 7.30-7.29 (m, 1H), 7.12-7.09 (m, 1H), 5.63 (s, 1H), 3.73 (s, 2H); 13C{1H}NMR (150MHz, CDCl3, ppm): 168.0, 163.4-161.8 (J=246Hz) ,134.1,129.9,129.9-129.0(J=8Hz),128.1,122.4-122.4(J=3Hz),118.1-118.0(J=21Hz),114.5-114.4(J=23Hz),52.3, 47.1; 11B{1H}NMR (160MHz, CDCl3, ppm): δ6.4(1B),-2.3(1B),-3.7(2B),-9.8(2B),-14.3(1B),-16.9(3B); HRMS(ESI)m / z calcd for C 15 H 19 B 10 FNO - (MH) - 357.24230, found 357.24356.
[0178] 25. Preparation of compound 2y:
[0179]
[0180] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 4-fluoro B(9)-amide-o-carborane 1a (29.8 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2y was separated by column chromatography to obtain 18.3 mg of the product 2y. The yield was 49%, which was in line with expectations.
[0181] NMR data: 1HNMR (600MHz, CDCl3, ppm): δ7.61-7.60 (m, 2H), 7.55-7.54 (m, 2H), 7.35-7.32 (m, 1H), 7.31-7.29 (m, 4H), 5.62 (s, 1H), 3.72 (s, 2H); 13C{1H}NMR (150MHz, CDCl3, ppm): 168.2 ,137.3,134.2,134.1,129.0,128.5,128.5,128.1,52.3,47.7; 11B{1H}NMR (160MHz, CDCl 3, ppm): δ6.4(1B),-2.4(1B),-3.7(2B),-9.8(2B),-14.3(1B),-17.0(3B); HRMS(ESI)m / z calcd for C 15 H 19 B 10 ClNO - (MH) - 373.21275, found 373.21371.
[0182] 26. Preparation of compound 2z:
[0183]
[0184] The B(9)-amide-o-carborane 1a (26.3 mg, 0.1 mmol) in the above 1 was replaced by 4-trifluoromethyl-B(9)-amide-o-carborane 1a (34.3 mg, 0.1 mmol). The other methods were the same as those described in the above 1 (the reaction equation is shown above). The product 2z was separated by column chromatography to obtain 16.3 mg of the product. The yield was 39%, which was in line with expectations.
[0185] NMR data: 1H NMR (500 MHz, CDCl3, ppm): δ 7.70 - 7.69 (d, 2H, J = 10 Hz), 7.62 - 7.58 (m, 4H), 7.34 - 7.29 (m, 3H), 5.67 (s, 1H), 3.74 (s, 2H); 13C{1H} NMR (125 MHz, CDCl3, ppm): 173.0, 128.7 - 128.5 (J = 25 Hz), 128.0 - 128.0 (J = 8 Hz), 127.9, 126.5, 125.8, 125.4, 123.8, 52.0, 47.4, 43.1; 11B{1H} NMR (160 MHz, CDCl3, ppm): δ 6.2 (1B), -2.9 (1B), -4.2 (1B), -10.1 (2B), -14.7 (1B), -17.7 (4B); HRMS (ESI) m / z calcd for C 16 H 19 B 10 F3NO - (M-H) - 407.23856, found 407.24042。
Claims
1. A B(4)-aryl-B(9)-amide-o-carborane derivative, Features: The derivative is represented by the following general formula (1): Among them, the R 1 is one of phenyl, substituted phenyl, benzyl, benzylnaphthalene or cyclopropyl; The R 2 It is one of phenyl, substituted phenyl or naphthyl.
2. The B(4)-aryl-B(9)-amide-o-carborane derivative according to claim 1, Features: The substituent of the substituted phenyl group is one of halogen, methyl, methoxy, trifluoromethyl, tert-butyl and acetyl.
3. The B(4)-aryl-B(9)-amide-o-carborane derivative according to claim 2, Features: The R 1 The substituent of the substituted phenyl group is one of halogen, methyl, methoxy, trifluoromethyl and tert-butyl; 2 The substituent of the substituted phenyl group is one of halogen, methyl, methoxy, trifluoromethyl, tert-butyl and acetyl.
4. A method for preparing the B(4)-aryl-B(9)-amide-o-carborane derivative as claimed in claim 1, Features: The preparation method of the derivative is represented by the following general formula (2): Using 9-amido-o-carborane derivatives as raw materials, Pd(MeCN) 4 (BF 4 ) 2 As catalyst, Cu(OAc) 2 and Ag 2 O is an oxidant, and the reaction is carried out in tetrahydrofuran, and potassium aryl trifluoroborate is used to selectively oxidatively couple with B(4)-H to prepare B(4)-aryl-B(9)-amide-o-carborane derivatives; Among them, the R 1 is one of phenyl, substituted phenyl, benzyl, benzylnaphthalene or cyclopropyl; The R 2 It is one of phenyl, substituted phenyl or naphthyl.
5. The method for preparing the B(4)-aryl-B(9)-amide-o-carborane derivative according to claim 4, Features: The substituent of the substituted phenyl group is one of halogen, methyl, methoxy, trifluoromethyl, tert-butyl and acetyl.
6. The B(4)-aryl-B(9)-amide-o-carborane derivative according to claim 5, Features: The R 1 The substituent of the substituted phenyl group is one of halogen, methyl, methoxy, trifluoromethyl and tert-butyl; 2 The substituent of the substituted phenyl group is one of halogen, methyl, methoxy, trifluoromethyl, tert-butyl and acetyl.
7. The preparation method according to claim 4, Features: The preparation method of the 9-amide-o-carborane derivative is as follows: (1) o-Carborane derivatives and dichloromethane, I 2 and AlCl 3 The catalyst reacts to obtain a 9-Io-carborane derivative; (2) 9-Io-Carborane derivatives and benzamide, Pd 2 (dba) 3 , K 3 PO 4 , DavePhos and toluene to obtain 9-amide-o-carborane derivatives.
8. The preparation method according to claim 7, It is characterized in that The method further comprises: (3) Filtration, concentration, and separation: After the reaction in step (2) is completed, the system temperature is cooled to room temperature and filtered through a short silica gel column using ethyl acetate as the eluent. The filtrate is concentrated under reduced pressure and then purified by column chromatography using petroleum ether / ethyl acetate = 5:1 as the eluent to obtain a B(4)-aryl-B(9)-amide-o-carborane derivative.
9. Use of the B(4)-aryl-B(9)-amide-o-carborane derivative according to claim 1 in the preparation of anti-tumor drugs.
Citation Information
Patent Citations
Preparation method of o-carborane indole and derivative thereof
CN115286652A
Preparation method of o-carborane substituted oxetane and derivative thereof
CN115368394A
